Yuka Sugimoto

Miemachi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Plasma-derived human protein C replacement concentrate therapy in a patient with severe congenital protein C deficiency presenting with purpura fulminans and disseminated intravascular coagulation

Plasma-derived human protein C replacement concentrate therapy in a patient with severe congenital protein C deficiency presenting with purpura fulminans and disseminated intravascular coagulation

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 01, 2026

New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.

New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms.

Journal: Leukemia

Published: October 04, 2025

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

Journal: International journal of hematology

Published: October 02, 2025

Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study.

Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study.

Journal: International journal of hematology

Published: August 25, 2025

Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.

Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.

Journal: International journal of hematology

Published: July 22, 2025

A rare CALR exon 9 mutation p.E379Vfs*53 in AYA generation exhibits gain-of-function nature and can induce essential thrombocythemia; a case report.

A rare CALR exon 9 mutation p.E379Vfs*53 in AYA generation exhibits gain-of-function nature and can induce essential thrombocythemia; a case report.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 06, 2025

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.

Journal: International journal of hematology

Published: May 16, 2025

Clinical characteristics of adolescents and young adults, and the relationship between neutrophil count/ratio and thrombosis in Japanese patients with polycythemia vera and essential thrombocythemia: sub-analyses of JSH-MPN-R18

Clinical characteristics of adolescents and young adults, and the relationship between neutrophil count/ratio and thrombosis in Japanese patients with polycythemia vera and essential thrombocythemia: sub-analyses of JSH-MPN-R18

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: May 11, 2025

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia.

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia.

Journal: EJHaem

Published: January 19, 2025

Correction to: Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.

Correction to: Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.

Journal: Annals of hematology

Published: August 21, 2024

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation.

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 20, 2024

Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.

Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.

Journal: International journal of hematology

Published: July 04, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026